Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

Abstract

Background and Objective Zibotentan, a selective endothelin A receptor antagonist, is in development for chronic liver and kidney disease. The pharmacokinetics (PK) of zibotentan were previously investigated in patients with either renal impairment or hepatic impairment, but the impact of both pathologies on PK was not evaluated. This study evaluated the PK and tolerability of a single oral dose of zibotentan in participants with concurrent moderate renal impairment and moderate hepatic impairment versus control participants. Methods Twelve participants with moderate renal and hepatic impairment and 11 healthy matched control participants with no clinically significant liver or kidney disease were enrolled in an open-label, parallel-group study design. After administration of a single oral dose of zibotentan 5 mg, blood and urine sampling was performed. Pharmacokinetic parameters were determined for each of the two cohorts and compared. Comparisons between the cohorts were based on the geometric least squares mean ratio for the primary endpoints, which were area under the plasma concentration-time curve (AUC) from time zero to infinity (AUC ∞ ) and from time zero to the time of the last measurable concentration (AUC last ), and maximum plasma drug concentration ( C max ) on Day 1 through 120 h post-dose. Secondary endpoints included apparent total body clearance (CL/F) on Day 1 through 120 h post-dose. Safety endpoints were assessed up to discharge. Results In total, 11 participants with concurrent moderate renal and hepatic impairment, and 11 controls, completed the study. Zibotentan was generally well tolerated, and no new clinically significant safety findings were observed. Total exposure (AUC ∞ and AUC last ) was approximately 2.10-fold higher in participants with concurrent moderate renal and hepatic impairment versus controls, while C max and total nonrenal body clearance were similar among all groups. A regression-based post hoc analysis, comparing exposure and CL/ F in patients with concurrent impairment to patients with either renal or hepatic impairment alone, showed that CL/ F with concurrent impairment was approximately half of that in controls and was positively correlated with reduction of renal function. Inclusion of the data on concurrent moderate renal and hepatic impairment in the regression analysis led to a narrower confidence interval for the predicted mean CL/ F in participants with moderate hepatic impairment. Conclusion The presented findings advance the understanding of the PK of zibotentan in both renal impairment and hepatic impairment, with and without overlapping pathologies, and will thus increase the confidence...

Precision Pharmacotherapy With Zibotentan in Microvascular Angina: a randomized, placebo-controlled, cross-over trial.

“…18 The median (interquartile range) zibotentan pre-dose plasma concentration in 81 participants was 137.0 [16.5, 426.0] ng/ml (range 1.0 to 1300 ng/ml), which is in line with expectations based on earlier clinical studies characterizing the pharmacokinetics of zibotentan. 19,20 The MRI substudy has provided mechanistic insights into the effects of the 10-mg dose of zibotentan in this population. The increases in ventricular volumes and myocardial native T1 relaxation time (Supplementary Table S6) revealed by MRI reflect fluid retention.…”